Clinical Trials Now Enrolling


RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT HIGH-GRADE GLIOMA

A Phase 0/2 study of ribociclib in combination with everolimus in preoperative Rb-intact recurrent high-grade glioma patients scheduled for resection


Visit ClinicalTrials.gov or use NCT identifier NCT03834740  to view inclusion criteria and additional study details.


RIBOCICLIB FOR RECURRENT MENINGIOMA

A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade meningioma patients scheduled for resection


Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.


RIBOCICLIB FOR RECURRENT GLIOBLASTOMA

A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection


Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.


SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA

A Phase 0 study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients


Visit ClinicalTrials.gov or use NCT identifier NCT04559685 to view inclusion criteria and additional study details.


PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Learn More

Visit ClinicalTrials.gov or use NCT identifier NCT04614909 to view inclusion criteria and additional study details.


INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA

A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort

Learn More

Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.


ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA

A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration

Learn More

Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.